Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alfred Beshai

Pain Medicine Irvine, CA Medical Doctor

NPI 1184834194 CMS profile 852310

16405 Sand Canyon Ave Ste 210, Ste 201, Irvine, CA 92618

Open in the dashboard

General payments

$15,527

454 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alfred Beshai of Irvine, CA is reported in the CMS Open Payments database as having received $15,527 across 454 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,607 35
2024 General $1,886 39
2023 General $3,106 74
2022 General $2,253 60
2021 General $2,523 74
2020 General $1,836 66
2019 General $2,317 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Beshai
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Alfred Beshai were reported at $1,607. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Alfred Beshai Pain Medicine median Middle half National median
2019 $2,317 $498 $126–$1,682 $163
2020 $1,836 $284 $80–$910 $114
2021 $2,523 $399 $112–$1,219 $132
2022 $2,253 $455 $137–$1,484 $149
2023 $3,106 $484 $128–$1,495 $160
2024 $1,886 $498 $131–$1,540 $164
2025 $1,607 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $9,596 226 payments
  2. Medtronic USA, Inc. $3,245 126 payments
  3. Boston Scientific Corporation $1,636 62 payments
  4. Nevro Corp. $329 20 payments
  5. Abbott Laboratories $322 6 payments
  6. Stryker Corporation $187 6 payments
  7. SI-BONE, Inc. $102 2 payments
  8. Painteq LLC $34 1 payment
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $27 2 payments
  10. Novartis Pharmaceuticals Corporation $23 1 payment
  11. Other $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,527 454 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $6,295 136 payments
  2. INTELLIS Spinal Cord Neurostimulation $2,661 110 payments
  3. INTELLIS Spinal Cord Neurostimulation $2,032 67 payments
  4. INCEPTIV $942 19 payments
  5. WaveWriter Alpha Prime 16 $664 28 payments
  6. RESTORE $578 15 payments
  7. GENERAL PAIN MANAGEMENT $495 16 payments
  8. Senza Spinal Cord Stimulation System $199 14 payments
  9. ETERNA $143 3 payments
  10. Proclaim Family of SCS IPGs $136 1 payment
  11. Other $979 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$709,659

Of which drugs: $11,892

Medicare patients

654

Average age 76

Services billed

52,750

380 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Ischemic heart disease 28%
Depression 24%
Osteoporosis 24%
Chronic kidney disease 22%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 12 850 $3,611
Injection, methylprednisolone acetate, 1 mg J1010 Office 329 33,067 $3,366
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 447 9,658 $2,856
Injection, methylprednisolone acetate, 40 mg J1030 Office 124 223 $1,115
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 420 581 $600
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 97 2,290 $206
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 58 2,480 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record